Ticker League

Revolution Medicines (RVMD) Free Cash Flow Bridge

Pinpoint what moved Revolution Medicines's FCF from TTM through Q1 2025 to TTM through Q1 2026 — operating cash flow shifts and capex changes, each driver sized in dollars.

Analysis
Capital Return

How this company returns cash to shareholders — buybacks, dividends, and stock splits.

TTM

FCF YoY

-78.11%

OCF YoY

-78.83%

Capex YoY

+37.04%

FCF Conversion Δ

Free cash flow bridge for Revolution Medicines (RVMD) — TTM through Q1 2026 vs TTM through Q1 2025

Δ Free cash flow: -$470M

FCF bridge breakdown for Revolution Medicines (RVMD) — TTM through Q1 2026 vs TTM through Q1 2025

  • Prior Free Cash Flow-$602M
  • Operating Cash Flow-$466M
  • Capital Expenditure-$3.86M
  • Free Cash Outflow-$1.07B
Identity check: drivers reconcile to ΔNI within $0.00
Want to see how cash flow is built up?Cash Flow Waterfall

Frequently asked questions

Data & methodology

Explore more

Deep-dives across the income statement, cash flow, capital return, and valuation